Nabriva Therapeutics is a commercial-stage biopharmaceutical company engaged in the development of novel antibiotics to treat serious infections. Nabriva Therapeutics has two products: lefamulin, recently approved by the FDA for both Oral and IV use and CONTEPO (fosfomycin) for injection, we submitted an NDA for CONTEPO, a potential first-in-class epoxide antibiotic in the United States for complicated urinary tract infections (cUTIs) including acute pyelonephritis (AP). Our corporate headquarters are in Dublin, Ireland with offices and labs located in Vienna, Austria and King of Prussia, PA. Source
No articles found.
ICU Medical, Inc. (Nasdaq:ICUI) develops, manufactures and sells innovative medica...
ICU Medical, Inc. (Nasdaq:ICUI) develops, manuf...
Tyme Inc. is an emerging biotechnology company developing cancer therapeutics that...
Tyme Inc. is an emerging biotechnology company ...
Pawprint is an app that allows you to streamline communication between veterinaria...
Pawprint is an app that allows you to streamlin...
Cyclerion Therapeutics is a clinical-stage biopharmaceutical company harnessing th...
Cyclerion Therapeutics is a clinical-stage biop...
SIGA Technologies, Inc. is a public, commercial-stage pharmaceutical company focus...
SIGA Technologies, Inc. is a public, commercial...
Synthorx is a biotechnology company focused on prolonging and improving the lives ...
Synthorx is a biotechnology company focused on ...
SIGA Technologies, Inc. is a public, commercial-stage pharmaceutical company focus...
SIGA Technologies, Inc. is a public, commercial...
Join the National Investor Network and get the latest information with your interests in mind.